# Idelalisib-Induced Pneumonitis in Chronic Lymphocytic Leukemia

## TL;DR

This paper discusses a case of lung inflammation caused by a drug used to treat chronic lymphocytic leukemia and emphasizes the need for early diagnosis and personalized treatment.

## Contribution

The paper presents a case report of idelalisib-induced pneumonitis and highlights the importance of early diagnosis and tailored treatment.

## Key findings

- Idelalisib, a PI3Kδ inhibitor, is effective in treating relapsed chronic lymphocytic leukemia.
- Idelalisib can cause pneumonitis, a serious side effect requiring early diagnosis and individualized treatment for better outcomes.

## Abstract

Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, effectively treats relapsed chronic lymphocytic leukemia (CLL). While this targeted approach offers a therapeutic edge, particularly in B-cell malignancies, it is associated with complications such as pneumonitis. This report details idelalisib-induced pneumonitis, highlighting the importance of early diagnosis and tailored treatment in achieving a favorable patient outcome.